Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3

Nail psoriasis is a chronic, difficult-to-treat condi-tion affecting almost half of patients with psoriasis. It is associated with considerable social stigma and impairment of patients' quality of life. The aim of this study was to assess improvements in objective measures of nail psoriasis among patients from the long-term extension of the UNCOVER-3 study who re-ceived the interleukin-17A inhibitor ixekizumab and had either any degree of nail psoriasis (Nail Psoria-sis Severity Index (NAPSI) >=1) or significant nail psoriasis (fingernail NAPSI >= 16 and >= 4 fingernails involved) at baseline. Efficacy outcomes reported th-rough week 264 included the mean percentage im-provements from baseline in NAPSI score and the proportion of patients achieving nail psoriasis reso-lution (NAPSI=0). In UNCOVER-3, 56.9% (219/385) of patients had nail psoriasis at baseline; of those, 61.2% (134/219) had significant nail psoriasis. At week 60, a total of 66.9% and 59.1% of patients with baseline nail psoriasis and significant baseline nail psoriasis, respectively, reported complete clea-rance of nail psoriasis, an effect which was sustained through week 264. This analysis demonstrates that continuous treatment with ixekizumab in adult patients with moderate-to-severe-psoriasis through 264 weeks was associated with improvements and clearance of fingernail psoriasis, irrespective of the severity of nail psoriasis at baseline.

Automated summary

This study evaluates the long-term effects of ixekizumab treatment on nail psoriasis, showing that continuous treatment can improve and clear nail psoriasis regardless of the severity at baseline.